103 related articles for article (PubMed ID: 9066696)
1. Cytotoxicity of CPT-11 against a Taxol-resistant cell line.
Matsuoka H; Yano K; Takiguchi S; Wakasugi H; Tomoda H
Anticancer Res; 1997; 17(1A):467-71. PubMed ID: 9066696
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
Takeda S; Shimazoe T; Kuga H; Sato K; Kono A
Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748
[TBL] [Abstract][Full Text] [Related]
5. Interactions between taxol and camptothecin.
Debernardis D; Cimoli G; Parodi S; Russo P
Anticancer Drugs; 1996 Jul; 7(5):531-4. PubMed ID: 8862720
[TBL] [Abstract][Full Text] [Related]
6. Advantage of combined treatment of CPT-11 and 5-fluorouracil.
Matsuoka H; Yano K; Takiguchi S; Kono A; Seo Y; Saito T; Tomoda H
Anticancer Res; 1995; 15(4):1447-52. PubMed ID: 7654033
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
8. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
10. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of CPT-11 and SN-38 for gastrointestinal and recurrent carcinomas cultured on contact-sensitive plates.
Matsuoka H; Furusawa M; Tomoda H; Seo Y; Kono A; Takeda S; Sato K
Anticancer Res; 1994; 14(2A):405-9. PubMed ID: 8017840
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
Aiba K; Funakoshi S; Mizunuma N; Dobashi N; Hirano A; Sano M; Kuraishi Y; Kamada M; Ohno N; Sugimoto Y
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1601-6. PubMed ID: 8060134
[TBL] [Abstract][Full Text] [Related]
13. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
[TBL] [Abstract][Full Text] [Related]
14. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells.
Parekh H; Wiesen K; Simpkins H
Biochem Pharmacol; 1997 Feb; 53(4):461-70. PubMed ID: 9105396
[TBL] [Abstract][Full Text] [Related]
16. Increased intracellular cAMP renders HL-60 cells resistant to cytotoxicity of taxol.
Pae HO; Yoo JC; Jun CD; Paik SG; Choi BM; Baek KH; Kim JM; Chung HT
Immunopharmacol Immunotoxicol; 1999 May; 21(2):233-45. PubMed ID: 10319278
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.
Nakatsu S; Kondo S; Kondo Y; Yin D; Peterson JW; Kaakaji R; Morimura T; Kikuchi H; Takeuchi J; Barnett GH
Cancer Chemother Pharmacol; 1997; 39(5):417-23. PubMed ID: 9054955
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
Jeansonne DP; Koh GY; Zhang F; Kirk-Ballard H; Wolff L; Liu D; Eilertsen K; Liu Z
Oncol Rep; 2011 May; 25(5):1473-80. PubMed ID: 21331447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
